David F. McDermott

基本信息

浏览量：41

职业迁徙

个人简介

DF/HCC PROGRAM AFFILIATION
Kidney Cancer, Co-Leader
Melanoma, Member
DF/HCC ASSOCIATIONS
Member, Center Scientific Council
Co-Associate Director, Clinical Science, Executive Committee

研究兴趣

论文共 785 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Updated Overall Survival in Patients with Prior Checkpoint Inhibitor Therapy in the Phase III TIVO-3 Study

Miguel Zugman,David F. Mcdermott,Bernard J. Escudier,Thomas E. Hutson,Camillo Porta,Elena Verzoni,Michael B. Atkins,Brian Rini,Sumanta K. Pal

ONCOLOGISTno. 2 (2025)

引用0浏览0WOS引用

Belzutifan Plus Cabozantinib As First-Line Treatment for Patients with Advanced Clear-Cell Renal Cell Carcinoma (LITESPARK-003): an Open-Label, Single-Arm, Phase 2 Study

Toni K. Choueiri,Jaime R. Merchan,Robert Figlin,David F. Mcdermott,Edward Arrowsmith,M. Dror Michaelson,Scott S. Tykodi,Elisabeth Heath,David R. Spigel,Anishka D'Souza, Laurent Kassalow,Rodolfo F. Perini,Donna Vickery,Todd M. Bauer

LANCET ONCOLOGY（2025）

引用0浏览0WOS引用

Intratumoral T-cell Infiltration and Response to Nivolumab Plus Ipilimumab in Patients with Metastatic Clear Cell Renal Cell Carcinoma from the CheckMate-214 Trial

Sayed Matar,Opeyemi Jegede,Thomas Denize,Fatme Ghandour,Yasmin Nabil Laimon,Nourhan El Ahmar,Aseman Bagheri Sheshdeh,Varunika Savla, Razan Assaad Mohanna,Paul J. Catalano,David A. Braun,Maxine Sun,Saurabh Gupta,Sai Vikram Vemula,Gordon J. Freeman,Robert J. Motzer,Michael B. Atkins,David F. McDermott,Toni K. Choueiri,Sabina Signoretti

Journal of Clinical Oncologyno. 16_suppl (2024): 4536-4536

引用0浏览0引用

68 Integrative Biomarkers Analysis from the Phase 3 CheckMate 914 Trial of Nivolumab Plus Ipilimumab or Nivolumab Versus Placebo for Adjuvant Clear Cell Renal Cell Carcinoma (Ccrcc)

Sai Vikram Vemula,Wenxin Xu, Aparajita Verma,Wiem Safta, Catherine Tang,Aparna Chhibber,David Paulucci,George Lee,Chung Wei Lee,Xiaowen Liu, Deepthi Chowbene,Nahuel Perrot,Paul Russo,Axel Bex,Viktor Grunwald,Toni K Choueiri,Saurabh Gupta,David F McDermott,Rupal Bhatt,Robert Motzer

Regular and Young Investigator Award Abstracts (2024)

引用0浏览0引用

Treatment-free Survival Outcomes from the Phase II Study of Nivolumab and Salvage Nivolumab/ipilimumab in Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

Michael B. Atkins,Opeyemi A. Jegede,Naomi B. Haas,David F. Mcdermott,Mehmet A. Bilen,Mark Stein,Jeffrey Sosman,Robert Alter,Elizabeth R. Plimack,Moshe C. Ornstein,Michael Hurwitz,David J. Peace,David Einstein,Paul J. Catalano,Hans Hammers,Meredith M. Regan

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2024）

引用1浏览0WOS引用

Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: the EMBARK Trial

David J Einstein,Meredith M Regan,Julia S Stevens,David F McDermott,Ravi A Madan

Journal of Clinical Oncology (2024)

引用1浏览0WOS引用

CDK4/6 Inhibition with Abemaciclib in in Patients (pts) with Previously Treated Advanced Renal Carcinoma (RCC)

Bradley McGregor,Wanling Xie,Wenxin Xu,Stephanie Berg,Srinivas R. Viswanathan,David McDermott,Sabina Signoretti,William Kaelin,Toni Choueiri

ONCOLOGIST (2024)

引用0浏览0WOS引用

1702P Updated Results of Phase II Study of Cabozantinib (cabo) with Nivolumab (nivo) and Ipilimumab (ipi) in Advanced Renal Cell Carcinoma with Divergent Histologies (Rccdh)

B.A. McGregor, M. Paul,W. Xie, W. Xu,M.A. Bilen,D.A. Braun,S. Berg, T. Zhang,R.R. McKay,D.F. McDermott,H. Hammers,T.K. Choueiri

Annals of Oncology (2024): S1020

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn

教授

论文共 785 篇作者统计合作学者相似作者